Evommune EVMN
NYSE EVMN
$5.18 -0.20 (-3.72%)
As of: Oct 21, 2026 · 3:59 PM EDT

Evommune (EVMN) Net Income (2024 - 2026)

Updated

Evommune (EVMN) recorded Net Income of -$32.24 million in Q2 2026, compared with -$22.59 million a year earlier.

Analysis

Evommune (EVMN) Net Income (2024 - 2026) Analysis & Trends

On a TTM basis, Evommune's Net Income came in at -$94.65 million as of Jun 30, 2026; for FY2025, it was -$77.75 million.

  • Across earlier years, Net Income came in at -$66.77 million in FY2024.
  • The Q2 2026 figure is the lowest quarterly Net Income in data going back to Q3 2024.
  • Per Business Quant, the preceding three quarters came in at -$21.67 million (Q1 2026), -$28.27 million (Q4 2025) and -$12.47 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 5.53 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 3.62 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 2.51 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -10.50 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -248.00 Mn
10 Evommune 186.46 Mn -451.06 Mn - -32.25 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.25 Mn
Mar 31, 2026 -21.67 Mn
Dec 31, 2025 -28.27 Mn
Sep 30, 2025 -12.48 Mn
Jun 30, 2025 -13.57 Mn
Mar 31, 2025 -14.56 Mn
Dec 31, 2024 -20.73 Mn
Sep 30, 2024 -15.90 Mn
API Access

Evommune Net Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income&ticker=EVMN&period=max&api_key=YOUR_API_KEY